Skip to main content
main-content
Top

22-04-2020 | Comorbidities | News

News in brief

ASCO launches cancer and COVID-19 registry

Author:
Shreeya Nanda

medwireNews: ASCO has initiated the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to collect point-in-time and longitudinal data on the outcomes of patients with cancer and comorbid COVID-19.

The registry is collating data not only on the symptoms and severity of the infection in cancer patients, but also on the impact of the pandemic on cancer care delivery and cancer outcomes. Data will be collected during the ongoing crisis and into 2021.

ASCO President Howard “Skip” Burris III (Sarah Cannon Research Institute, Nashville, Tennessee, USA) said in a press statement: “The cancer care community needs data on how the virus is impacting our patients, their cancer treatment, and outcomes to inform current cancer care and decision-making for future disease outbreaks.

“We encourage all oncology practices to participate so that we can learn from every patient, in every practice, in every state across the country.”

All US oncology practices can participate in the website-based registry, which will include data on COVID-19 and cancer status, treatment, and outcomes, as well as information on demographics and comorbidities. As explained in the registry study schema, updates on COVID-19 status will need to be provided weekly, while cancer status will be updated monthly.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

22 April 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Related topics